Bormioli Pharma will collaborate with Chiesi, an international research-oriented biopharmaceutical company (Chiesi Group), for the supply of PET Carbon Capture bottles. The containers will be used to package a medicine indicated for the prophylaxis and treatment of seasonal and perennial allergic rhinitis and vasomotor rhinitis.
This supply introduces the use of a Carbon Capture PET bottle in the pharmaceutical industry for the first time, bringing environmental benefits and high levels of patient safety. Carbon Capture PET bottles enable a 21,9% reduction per kg of CO2 equivalent compared to traditional PET, whilst maintaining extractable levels comparable to standard PET.
Carbon Capture PET is a type of PET plastic produced by capturing carbon emissions, which are transformed through a fermentation process into BioMEG, the key molecule for PET production. The material is recyclable and maintains the same mechanical and physical performance as traditional PET.
"The agreement reached with Chiesi to manufacture one of its products using Carbon Capture PET bottles demonstrates both the performance and safety of these containers and the pharmaceutical industry's growing commitment to sustainability," he said. Andrea Lodetti, CEO of Bormioli Pharma“For Bormioli Pharma, this is a further recognition of the high quality levels achieved by our packaging solutions. To date, almost half of our sales are products made from low-impact materials thanks to the development of EcoPositive, one of the largest sustainable pharmaceutical packaging offerings, which includes over 3000 glass and plastic items.”
Two international leaders in sustainable solutions have also contributed: LanzaTech Global (Nasdaq: LNZA), a carbon recycling company whose technology is responsible for capturing and recycling carbon emissions that are transformed into CarbonSmart™ MEG, and Plastipak, a pioneer in innovative packaging and recycling solutions worldwide, which produces